- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Maria Elvira Salazar trades in Amgen, Carrier Global, and Microsoft stocks | 14 | Investing.com | ||
| AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
| Sa | Amgen Q1 2026: Sechs Wachstumstreiber sorgen für 24 % Expansion | 21 | Investing.com Deutsch | ||
| Sa | Amgen Q1 2026 slides: six growth drivers fuel 24% expansion | 10 | Investing.com | ||
| Sa | Amgen übertrifft Gewinnprognose für Q1 2026, Aktie gibt dennoch nach | 19 | Investing.com Deutsch | ||
| 07.05. | Freedom Broker stuft Amgen auf 'Kaufen' hoch: Wachstumstreiber intakt | 20 | Investing.com Deutsch | ||
| 07.05. | Amgen stock rating upgraded to buy at Freedom Broker on growth | 10 | Investing.com | ||
| 05.05. | Erste Group cuts Amgen stock rating on slowing sales growth | 10 | Investing.com | ||
| 04.05. | Amgen to spend another $300M on US manufacturing | 4 | Seeking Alpha | ||
| 04.05. | Amgen Invests Additional $300 Million in U.S. Manufacturing Network | 3 | Contract Pharma | ||
| 04.05. | Amgen to invest additional $300 million to boost US manufacturing footprint | 4 | Reuters | ||
| 04.05. | Amgen-Aktie gibt trotz 300-Millionen-Investition in Puerto Rico nach | 23 | Investing.com Deutsch | ||
| 04.05. | Amgen To Invest Additional $300 Mln In US Manufacturing Network | 474 | AFX News | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday revealed its plan to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity.... ► Artikel lesen | |
| 04.05. | Baron Health Care Fund's Performance Impacted by Amgen (AMGN) Omission | 16 | Insider Monkey | ||
| 04.05. | Amgen investiert 300 Millionen US-Dollar in Produktionsstandort in Puerto Rico | 13 | Investing.com Deutsch | ||
| 04.05. | Amgen channels another $300M into US outlay, bolstering Puerto Rico biologics expansion | 5 | FiercePharma | ||
| 04.05. | Amgen Announces Additional $300 Million U.S. Manufacturing Investment, Totaling Nearly $2 Billion Over The Last Year | 211 | PR Newswire | Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology
THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:... ► Artikel lesen | |
| 04.05. | Guggenheim cuts Amgen stock price target to $340 on valuation | 19 | Investing.com | ||
| 01.05. | ROUNDUP 2: Amgen hebt Jahresprognose an - Aktie gibt aber nach | 614 | dpa-AFX | (Kurs aktualisiert) THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt trotz zunehmender Konkurrenz zuversichtlicher auf das laufende Jahr. 2026 werde der Umsatz bei 37,1 bis 38,5 Milliarden... ► Artikel lesen | |
| 01.05. | Repatha sales help Amgen overcome Prolia biosimilar hits in 1st quarter | 19 | FiercePharma | ||
| 01.05. | Amgen hebt Jahresprognose an | 24 | cash |
1 2 3 4 5 Weiter >>
311 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RELAY THERAPEUTICS | 13,220 | 0,00 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | 0,00 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | 0,00 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | 0,00 % | Allogene Therapeutics Q1 2026 Earnings Call Transcript | ||
| TANGO THERAPEUTICS | 25,510 | 0,00 % | Jefferies downgrades Tango Therapeutics stock rating on valuation | ||
| C4 THERAPEUTICS | 3,660 | -0,54 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | -0,11 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | 0,00 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,860 | 0,00 % | Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA | ||
| ERASCA | 10,450 | -0,10 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 28,810 | 0,00 % | Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights | TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial... ► Artikel lesen | |
| CG ONCOLOGY | 74,06 | +0,08 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| VERA THERAPEUTICS | 39,180 | +0,08 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
AMGEN INC CDR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 15,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC CDR finden Sie auf Wallstreet Online.